Medtronic Presents Real-World Data of InPen Smart Insulin Pen for Controlling Blood Sugar Levels at ADA2021
Shots:
- The real-world clinical study compares glycemic outcomes for 1-736 individuals before & after using the InPen smart insulin pen for 90days with a CGM & showed a 2.3% increase in time in range for people with glucose GMI ( >8%) and 5% increase time in range for patients with GMI (>9.5%).
- Additionally- no patients have incidents of low blood sugar during the study period. The InPen also showed improvements in overall insulin dosing
- Along with the InPen study- the company also presents results from extended-use insulin infusion tubing which showed no significant increase in the total daily dose of insulin. The infusion set can be worn for up to seven days- no severe adverse events identified
Ref: Medtronic | Image: Medtronic
Click here to read the full press release
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com
